New Preclinical Model Offers Insights into Parkinson's Disease and Possible Detection Method

Researchers at Weill Cornell Medicine have developed a new preclinical model for studying Parkinson's disease that involves knocking out a key component involved in protein transportation in the light-sensing rod cells of mice. This model leads to the retinal accumulation of alpha-synuclein aggregates, which are found in patients with Parkinson's disease. The study, published in Nature Communications, suggests a relatively easy method for detecting the disease in people.

Key Takeaways:

• The new preclinical model offers a unique platform for studying Parkinson's disease, with a rapidly developing disease process and no artificial modification to the mice's alpha-synuclein.
• The model mimics the pathology of human Parkinson's disease, with retinal accumulation of alpha-synuclein aggregates and visual impairment similar to seen in patients.
• Knocking out the VPS35 gene, which helps cells to distribute molecules to their corresponding destinations, leads to the formation of alpha-synuclein aggregates and Lewy bodies.
• The researchers found evidence that VPS35 works not just in disposing of aggregated alpha-synuclein but also in preventing its aggregation.
• The new model could be useful for studying disease mechanisms and testing potential therapies.
• Even in young mice, the rods lacking VPS35 soon lost their synapses, resulting in visual impairment similar to seen in patients with Parkinson's.

Statistics:

• Approximately 1 million Americans are affected by Parkinson's disease.
• The disease is diagnosed in the United States at the rate of about 90,000 new cases annually.
• Visual impairment is an early symptom of Parkinson's disease, affecting up to 70% of patients.
• Alpha-synuclein aggregates are found in 80-90% of Parkinson's disease patients.

Sources:

• Nature Communications, July 23
• Weill Cornell Medicine
• National Eye Institute
• National Institute on Aging